FGFR3 and pachyonychia congenita: In term of RECIST response, in the “matched therapy group” (Figure 4), one BRCA2-mutated PC patient (8%) experimented complete response (CR: 8%) with olaparib, three patients displayed partial response (PR: 25%), including one with urothelial cancer and FGFR3 mutation treated with infigratinib, one with PC and BRCA2 deletion treated with pembrolizumab/olaparib combination, and one with PC and PIK3R1 deletion treated with everolimus.